This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These cells are like ‘keys on a piano’ and range from low to high frequency, explains Dr Robert Gay, director of pharmaceutical approaches at Cochlear, a Sydney-based manufacturer of the device. The idea of using optical stimulation to overcome the bottleneck of poor spectral selectivity could be transforming.
Can you give us a deeper view of your company’s solutions for the EV industry, particularly for aspects like battery safety, electric motor design, power electronics, and transmission? At the same time, growth in the manufacturing of electronic gadgets in India has opened a new avenue for Indian Industry.
High-heat Casters and Wheels Excel in Demanding Environments Booth S-17200: Built to endure extreme temperatures, Hamilton’s high-heat casters and wheels excel in demanding environments such as autoclaves, powder coating systems, food manufacturing, and pharmaceutical industries.
This agreement removes a key bottleneck to advancing Tb-161-based therapies, and we look forward to contributing to the progression of these treatments into late-stage clinical trials.” This mechanism may deliver precise therapeutic benefits while reducing side effects compared to alpha-emitting isotopes.
We organize all of the trending information in your field so you don't have to. Join 45,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content